Prelude Therapeutics vs Tango Therapeutics
PRLD and TNGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PRLD and TNGX compare
Tango Therapeutics is the larger company, worth 14 times as much as Prelude Therapeutics ($3.7B against $265M).
Prelude Therapeutics grew revenue faster over the last twelve months (220% versus 121% for Tango Therapeutics).
Tango Therapeutics keeps more of each dollar of sales as profit, with a net margin of −230% compared with −270% at Prelude Therapeutics.
Tango Therapeutics scores higher on the StockData Score (10 against 8 for Prelude Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PRLD | TNGX |
|---|---|---|
| Size and price | ||
| Market cap | $265M | $3.7B |
| Share price | $3.32 | $22.11 |
| Change, 1 year | 118% | 171% |
| Change, 5 years | −76.3% | 114% |
| Beta (5Y) | 1.44 | 1.67 |
| Employees | 79 | 137 |
| StockData Score | ||
| Total score | 8 | 10 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 1 | 2 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 11.8× (better) | 69.3× |
| P/B | 2.0× (better) | 3.6× |
| FCF yield | −12.6% | −3.9% (better) |
| Fair value | $2.14 | $9.71 |
| Margin of safety | −55.2% (better) | −128% |
| Growth | ||
| Revenue growth (TTM) | 220% (better) | 121% |
| Revenue growth, 5Y average | – | 52.1% |
| Profitability | ||
| Operating margin | −301% | −253% (better) |
| Net margin | −270% | −230% (better) |
| FCF margin | −148% (better) | −268% |
| Return on equity | −57.7% | −21.3% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 4.07 | 50.82 (better) |
| Altman Z-score | −2.69 | 45.17 (better) |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 62.2% | 127% |
| Held by insiders | 40.5% | 11.7% |
| Insider net buying, 12 months | $25.0M (better) | −$8.1M |
| Short interest, % of float | 8.8% | 32.4% |
Go deeper
- PRLD stock overview
- PRLD income statement
- PRLD valuation and score
- TNGX stock overview
- TNGX income statement
- TNGX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.